Biotech Company Looks to Create Cheaper Alternatives to Pfizer, AstraZeneca Drugs
July 23, 2020
EQRX, a private biotech company launched in January, is looking to create cheaper alternatives to Pfizer’s Ibrance and AstraZeneca’s Tagrisso, according to an Evaluate report.
According to the report, EQRX has licensed two projects to bring its plan to fruition: G1’s lerociclib and Jiangsu Hansoh’s almonertinib.
To read the full report on Evaluate, click here.
